Highlights

• Beta Drugs shares declined nearly 9% despite reporting quarterly profit growth in Q4 FY26.
• The stock slipped below short-term momentum levels after recent volatility in pharma counters.
• RSI weakened sharply while price action moved near key support zones on daily charts.

Overview

Beta Drugs Limited (NSE: BETA) remained under pressure during Friday’s trading session, with the stock falling nearly 9% to around INR 1,277.50. The decline came after the company reported its Q4 FY26 financial results. The stock opened lower at INR 1,350.00 and touched an intraday low of INR 1,225.00 before attempting a mild recovery.

The sharp decline also followed recent volatility across broader healthcare and pharma stocks, where investors reacted cautiously to earnings announcements and valuation concerns.

Fundamental View

For the quarter ended March 2026, Beta Drugs reported consolidated total income of INR 9,685.92 lakh. Profit before tax stood at INR 1,183.14 lakh, while net profit came in at INR 904.89 lakh. Earnings per share for the quarter was reported at INR 8.93.

Although the company remained profitable during the quarter, market participants appeared cautious after the stock’s recent upward move in previous sessions. The reaction suggests investors may be evaluating future earnings consistency, margin trends, and growth visibility after the latest numbers.

Technical View

Beta Drugs stock closed near INR 1,277.50, down 8.98% in the session. The stock moved close to its 50-day SMA near INR 1,259.83, indicating weakening short-term momentum after recent consolidation around higher levels.

Price action reflects increased volatility following the sharp intraday decline, while the 14-day RSI slipped near 43.77, showing fading momentum compared to earlier sessions. The stock also witnessed heavy intraday selling pressure after failing to hold above the INR 1,350 zone.

Key Technical Levels

• Immediate Support: INR 1,130–1,025
• Immediate Resistance: INR 1,290–1,387

Risks to Watch

• Pharma sector volatility may impact near-term sentiment.
• Failure to hold above moving averages could pressure momentum further.
• Margin fluctuations may affect future earnings visibility.
• Broader market weakness could increase selling pressure in midcap stocks.

Summary

Beta Drugs shares witnessed a sharp correction after the company announced its Q4 FY26 earnings. While the company remained profitable during the quarter, the market reaction stayed cautious as traders booked profits following recent gains. Technically, the stock has moved near an important support area after slipping below key short-term levels. Future price movement may depend on earnings consistency, sector sentiment, and the stock’s ability to stabilize near current zones.

FAQs

Why did Beta Drugs shares fall today?

The stock declined after Q4 FY26 earnings and increased selling pressure during the session.

What were Beta Drugs’ Q4 FY26 earnings numbers?

The company reported INR 904.89 lakh net profit with EPS of INR 8.93.

What are the important levels for Beta Drugs stock?

Support is placed near INR 1,130–1,025, while resistance is seen around INR 1,290–1,387.